{
    "clinical_study": {
        "@rank": "26951", 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for refractory\n      mucocutaneous herpes simplex virus disease in AIDS patients. To determine whether topical\n      HPMPC therapy can induce re-epithelialization and healing of refractory mucocutaneous herpes\n      simplex virus disease in AIDS patients. To evaluate the virologic effects of topical HPMPC\n      therapy on herpes simplex virus shedding from refractory lesions."
        }, 
        "brief_title": "A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS", 
        "condition": [
            "Herpes Simplex", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Herpes Simplex"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive topical therapy with placebo (vehicle alone) or HPMPC at\n      either 0.3 or 1.0 percent once daily for 5 days. Patients are assessed to day 15; those with\n      no significant toxicity are eligible to receive open-label topical HPMPC for up to 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Antiretroviral therapy with AZT, ddI, ddC, or d4T.\n\n          -  Oral trimethoprim/sulfamethoxazole.\n\n          -  Dapsone.\n\n          -  Atovaquone.\n\n          -  Fluconazole.\n\n          -  Rifabutin.\n\n          -  Clarithromycin.\n\n        Patients must have:\n\n          -  HIV seropositivity.\n\n          -  Mucocutaneous herpes simplex virus (HSV) infection confirmed by previous viral\n             culture and persisting without improvement despite at least 10 days of acyclovir at a\n             minimum dose of 1 g/day (oral) or 15 mg/kg/day (intravenous).\n\n          -  Measurable lesions.\n\n          -  Consent of parent or guardian if less than 18 years of age.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n        Active medical problems sufficient to hinder study compliance or assessment of treatment\n        effect.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Acyclovir.\n\n          -  Immunomodulators (such as corticosteroids or interferons).\n\n          -  Lymphocyte replacement therapy.\n\n          -  Biologic response modifiers.\n\n          -  Ganciclovir.\n\n          -  Foscarnet.\n\n          -  Vidarabine.\n\n          -  Topical trifluridine.\n\n          -  Other investigational drugs (except d4T).\n\n          -  Amphotericin.\n\n          -  Intravenous therapy for PCP.\n\n          -  Chemotherapeutic agents.\n\n        Prior Medication:\n\n        Excluded within 14 days prior to study entry:\n\n          -  Immunomodulators (such as corticosteroids or interferons).\n\n          -  Lymphocyte replacement therapy.\n\n          -  Biologic response modifiers.\n\n          -  Ganciclovir.\n\n          -  Foscarnet.\n\n          -  Vidarabine.\n\n          -  Topical trifluridine.\n\n          -  Other investigational drugs with potential anti-HSV activity.\n\n          -  Amphotericin.\n\n          -  Intravenous therapy for PCP.\n\n        Excluded within 4 weeks prior to study entry:\n\n          -  Chemotherapeutic agents.\n\n        Required:\n\n          -  At least 10 days of prior acyclovir at a minimum dose of 1 g/day (oral) or 15\n             mg/kg/day (intravenous).\n\n        Substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002116", 
            "org_study_id": "218A", 
            "secondary_id": "GS-93-301"
        }, 
        "intervention": {
            "intervention_name": "Cidofovir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cidofovir"
        }, 
        "keyword": [
            "Herpes Simplex", 
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents", 
            "cidofovir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Los Angeles County - USC Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Mount Zion Med Ctr / UCSF"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "UCSF - San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush Presbyterian - Saint Luke's Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Univ of North Carolina Hosps"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77004"
                    }, 
                    "name": "Park Plaza Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98122"
                    }, 
                    "name": "Univ of Washington / Viral Disease Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "Univ of British Columbia / Univ Hosp"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "official_title": "A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "11364104", 
            "citation": "[No authors listed] Acyclovir-resistant herpes: expanded access available for cidofovir gel (Forvade). AIDS Treat News. 1997 Feb 7;(No 264):5. No abstract available."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002116"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1995"
    }, 
    "geocoordinates": {
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "Los Angeles County - USC Med Ctr": "34.052 -118.244", 
        "Mount Zion Med Ctr / UCSF": "37.775 -122.419", 
        "Park Plaza Hosp": "29.76 -95.369", 
        "Rush Presbyterian - Saint Luke's Med Ctr": "41.878 -87.63", 
        "UCSF - San Francisco Gen Hosp": "37.775 -122.419", 
        "Univ of British Columbia / Univ Hosp": "49.261 -123.114", 
        "Univ of North Carolina Hosps": "35.913 -79.056", 
        "Univ of Washington / Viral Disease Clinic": "47.606 -122.332"
    }
}